A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
A legfontosabb adatok
- Ki végzi
- ModernaTX, Inc.
- Hol
- Anderson, Austin, Baton Rouge, Beaumont, Birmingham, Bountiful, Brandon, Chamblee, Charlotte, Cleveland, Dallas, Doral, Endwell, Forest, Garden Grove, Grand Island, Greenville, Hialeah, Honolulu, Jacksonville, Knoxville, Lake Charles, Laredo, Las Vegas, Lilburn, Lincoln, Long Beach, Miami, Miami Lakes, Minneapolis, Modesto, Moore, Myrtle Beach, New York, Norcross, Norfolk, Omaha, Overland Park, Panorama City, Pomona, Portsmouth, Raleigh, Rockville, San Antonio, San Diego, Savannah, Sioux City, Spartanburg, Springdale, Springville, The Bronx, Tucson, Tustin és Waterbury (Egyesült Államok)Mind a 62 helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 3. fázis
- Résztvevők
- 3317 fő vett részt
- Kezdés
- 2022. ápr. 1.
- Befejezés
- 2024. nov. 8.
- A vizsgálat típusa
- Beavatkozással járó, 7 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Placebo
- mRNA-1345
- Afluria® Quadrivalent
- mRNA-1273.214
- A regiszteradat frissítve
- 2025. december 30.
Ki vehet részt
- Életkor
- 50 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 20 feltétel megnézéseKevesebb
Ki vehet részt
- Parts A and B both:
- Adults ≥50 years of age on the day of the Randomization Visit (Day 1) who are primarily responsible for self-care and activities of daily living. Participants may have one or more chronic medical diagnoses, but should be medically stable as assessed by: Absence of changes in medical therapy within 1 month due to treatment failure or toxicity; Absence of medical events qualifying as SAEs within 1 month of the planned vaccination on Day 1; and absence of known, current, and life-limiting diagnoses which, in the opinion of the investigator, would make completion of the protocol unlikely
- Able to comply with study requirements, including access to transportation for study visits; Part B only:
- Fully vaccinated for COVID-19 with an approved primary series according to the locally authorized or approved regimen. If the most recent COVID-19 vaccine was part of a primary series, it must be ≥ 150 days before (or less per local guidance) Day 1. If the most recent COVID-19 vaccine was a booster dose, it must be ≥ 120 days before (or less per local guidance) Day 1; Part C:
- Participants at Part C study sites who have been enrolled in Part B (Groups 4 and 5) of this study; have immunogenicity blood sampling at Part B baseline and Day 29; completed the Day 211/end-of-study visits for Part B; were included in the per-protocol (PP) set; and received 1 dose of mRNA-1345 at least 12 months (but no later than 15 months) prior to the time of enrollment
- Able to comply with study requirements, including access to transportation for study visits
Ki nem vehet részt
- Participant has received or plans to receive any vaccine authorized or approved by a local health agency ≤28 days prior to study injections (Day 1) or plans to receive a vaccine authorized or approved by a local health agency within 28 days after the study injections
- Prior participation in research involving receipt of any investigational product (drug/biologic/device including any investigational RSV product) within 45 days before the planned date of the Day 1 study injection
- Participant has received a seasonal influenza vaccine or any other investigational influenza vaccine ≤180 days prior to the Randomization Visit (Day 1)
- History of a serious reaction to any prior vaccination, or Guillain-Barré syndrome within 6 weeks of any prior influenza immunization
- Participated in an interventional clinical study within 28 days prior to the Screening Visit based on the medical history interview or plans to do so while participating in this study; Part B:
- Participant has received or plans to receive any vaccine authorized or approved by a local health agency ≤ 28 days prior to study injections (Day 1) or plans to receive a vaccine authorized or approved by a local health agency within 28 days after the study injections (with the exception of SARS-Cov-2 vaccination)
- Prior participation in research involving receipt of any investigational product (drug/biologic/device with the exception of RSV investigation products) within 45 days before the planned date of the Day 1 study injection
- Prior receipt of any investigational/approved RSV product within 1 year of the Day 1 study injection
- Has known history of SARS-CoV-2 infection within 90 days prior to enrollment; Parts A and B both:
- Participation in another interventional clinical research study where participant has received an investigational product (drug/biologic/device) within 6 months before the planned date of the BD Day 1 study injection. Any prior receipt of an investigational or approved vaccine against RSV, except as part of mRNA-1345 Study P302 Part B, is exclusionary
- Participant has received or plans to receive any vaccine authorized or approved by a local health agency ≤28 days prior to the study injection (BD Day 1) or plans to receive a vaccine authorized or approved by a local health agency within 28 days after the study injections
- History of a serious reaction to any prior vaccination or Guillain-Barré syndrome 6 weeks after any prior influenza immunization; Other inclusion and/or exclusion criteria may apply
- Participant had significant exposure to someone with SARS-CoV-2 infection or COVID-19 in the past 10 days, as defined by the United States (US) Centers for Disease Control and Prevention (CDC) as a close contact of someone who has had COVID-19; Part C:
- Part A:
Helyszínek itt: Egyesült Államok
- Velocity Clinical Research - Anderson - ERN - PPDSAnderson, Egyesült Államok
- Benchmark Research - Austin - HyperCore - PPDSAustin, Egyesült Államok
- Meridian Clinical Research (Baton Rouge-Louisiana) - Platinum - PPDSBaton Rouge, Egyesült Államok
- Tekton Research - Beaumont - Platinum - PPDSBeaumont, Egyesült Államok
- Central Research Associates, IncBirmingham, Egyesült Államok
- Cope Family Medicine Ogden ClinicBountiful, Egyesült Államok
- Teradan Clinical TrialsBrandon, Egyesült Államok
- Tekton Research - Georgia - Platinum - PPDSChamblee, Egyesült Államok
- Javara Research Inc. - Charlotte - Javara - PPDSCharlotte, Egyesült Államok
- Velocity Clinical Research - Cleveland - ERN - PPDSCleveland, Egyesült Államok
- Zenos Clinical ResearchDallas, Egyesült Államok
- Dolphin Medical ResearchDoral, Egyesült Államok
- Revival Research Corporation - Clinedge - PPDSDoral, Egyesült Államok
- Meridian Clinical Research (Endwell-New York) - Platinum - PPDSEndwell, Egyesült Államok
- Javara Inc./Privia Medical Group INCForest, Egyesült Államok
- Paragon RX Clinical, Inc.Garden Grove, Egyesült Államok
- Meridian Clinical Research (Grand Island) - Platinum - PPDSGrand Island, Egyesült Államok
- Velocity Clinical Research - Greenville - ERN - PPDSGreenville, Egyesült Államok
- Indago Research and Health CenterHialeah, Egyesült Államok
- East-West Medical Research InstituteHonolulu, Egyesült Államok
- Westside Center for Clinical Research - ERN - PPDSJacksonville, Egyesült Államok
- New Phase Research & DevelopmentKnoxville, Egyesült Államok
- Clinical Trials of SWLA, LLCLake Charles, Egyesült Államok
- Milton Haber, M.D.Laredo, Egyesült Államok
- Clinical Research Center of Nevada - ERN - PPDSLas Vegas, Egyesült Államok
- Santa Rosa Medical Centers of Nevada/ CCT ResearchLas Vegas, Egyesült Államok
- Lifeline Primary Care/ CCT ResearchLilburn, Egyesült Államok
- Be Well Clinical Studies LLCLincoln, Egyesült Államok
- Meridian Clinical Research, LLC (Lincoln Nebraska) - Platinum - PPDSLincoln, Egyesült Államok
- Ark Clinical ResearchLong Beach, Egyesült Államok
- Long Beach Clinical Trials, LLC (Site 1)Long Beach, Egyesült Államok
- Long Beach Clinical Trials, LLC (Site 2)Long Beach, Egyesült Államok
- Suncoast Research Associates LLC - ERN - PPDSMiami, Egyesült Államok
- Suncoast Research Group LLC - ERN-PPDSMiami, Egyesült Államok
- Floridian Clinical Research - ClinEdge - PPDSMiami Lakes, Egyesült Államok
- Clinical Research Institute, Inc - CRN - PPDSMinneapolis, Egyesült Államok
- Central Valley Research, LLCModesto, Egyesült Államok
- Tekton ResearchMoore, Egyesült Államok
- Trial Management Associates LLC - ERN - PPDSMyrtle Beach, Egyesült Államok
- IMA Medical Research, PC.New York, Egyesült Államok
- Georgia Clinic / CCT ResearchNorcross, Egyesült Államok
- Meridian Clinical ResearchNorfolk, Egyesült Államok
- Meridian Clinical Research (Omaha-Nebraska) - Platinum - PPDSOmaha, Egyesült Államok
- Midwest Regional Health Services - CCT ResearchOmaha, Egyesült Államok
- Meridian Clinical Research, LLC (Overland Park, Kansas) - Platinum - PPDSOverland Park, Egyesült Államok
- Velocity Clinical Research, Panorama CityPanorama City, Egyesült Államok
- Empire Clinical ResearchPomona, Egyesült Államok
- Meridian Clinical Research - Family Practice Ports - Portsmouth - Platinum - PPDSPortsmouth, Egyesült Államok
- M3 Wake Research, Inc - M3 WR - ERN - PPDSRaleigh, Egyesült Államok
- Meridian Clinical Research (Rockville Maryland) - Platinum - PPDSRockville, Egyesült Államok
- Sun Research InstituteSan Antonio, Egyesült Államok
- Acclaim Clinical ResearchSan Diego, Egyesült Államok
- Medical Center For Clinical Research - M3 WR - ERN - PPDSSan Diego, Egyesült Államok
- Meridian Clinical Research (Savannah Georgia) - Platinum - PPDSSavannah, Egyesült Államok
- Meridian Clinical Research (Sioux City - Iowa)Sioux City, Egyesült Államok
- Velocity Clinical Research - Spartanburg - ERN - PPDSSpartanburg, Egyesült Államok
- Meridian Clinical Research - Cincinnati - Platinum - PPDSSpringdale, Egyesült Államok
- CCT Research at Springville DermatologySpringville, Egyesült Államok
- CHEAR Center LLC - ClinEdge - PPDSThe Bronx, Egyesült Államok
- Del Sol Research Management - ClinEdge - PPDSTucson, Egyesült Államok
- Ark Clinical ResearchTustin, Egyesült Államok
- Chase Medical Research, LLCWaterbury, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine (Afluria® Quadrivalent); to evaluate the impact of coadministered influenza vaccine on the immune response to RSV-A; and to evaluate the impact of coadministered RSV vaccine on the immune response to influenza.
A teljes eredeti leírásKevesebb
The main purposes of Part B of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with mRNA-1273.214; to evaluate the effect of coadministered mRNA-1273.214 on the immune response to RSV-A; and to evaluate the effect of coadministered RSV vaccine on the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The main purposes of Part C (single arm, open-label) of this study are to evaluate the safety and tolerability of a booster dose (BD) of mRNA-1345 administered at 1 Year following a primary dose; to evaluate the immune response to RSV-A of a BD of mRNA 1345 administered at 1 Year following a primary dose; and to evaluate the immune response to RSV-B of a BD of mRNA-1345 administered at 1 Year following a primary dose.
A vizsgálat 7 csoportja
- Part A: mRNA-1345 + PlaceboA vizsgált kezelés
Single injection of mRNA-1345 and placebo, administered intramuscularly (IM), one in each arm on Day 1.
Kezelés: Placebo és mRNA-1345
- Part A: mRNA-1345 + Afluria® QuadrivalentA vizsgált kezelés
Single injection of mRNA-1345 and Afluria® quadrivalent, administered IM, one in each arm on Day 1.
Kezelés: mRNA-1345 és Afluria® Quadrivalent
- Part A: Afluria® Quadrivalent + PlaceboMár használt kezelés, összehasonlításként
Single injection of Afluria® quadrivalent and placebo, administered IM, one in each arm on Day 1.
Kezelés: Placebo és Afluria® Quadrivalent
- Part B: mRNA-1345 + PlaceboA vizsgált kezelés
Single injection of mRNA-1345 and placebo, administered IM, one in each arm on Day 1. An additional injection of mRNA-1273.214, administered on Day 29.
Kezelés: Placebo, mRNA-1345 és mRNA-1273.214
- Part B: mRNA-1345 + mRNA-1273.214A vizsgált kezelés
Single injection of mRNA-1345 and mRNA-1273.214, administered IM, one in each arm on Day 1. An additional injection of placebo administered on Day 29.
Kezelés: Placebo, mRNA-1345 és mRNA-1273.214
- Part B: mRNA-1273.214 + PlaceboMár használt kezelés, összehasonlításként
Single injection of mRNA-1273.214 and placebo, administered IM, one in each arm on Day 1. An additional injection of placebo administered on Day 29.
Kezelés: Placebo és mRNA-1273.214
- Part C: mRNA-1345A vizsgált kezelés
Single injection of mRNA-1345 administered IM on BD Day 1.
Kezelés: mRNA-1345
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered With a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults ≥ 50 Years of Age
- Publikációk
- A regiszteradat frissítve
- 2025. december 30.